ChiCTR2000039421 版本V1.1 版本创建时间2020/10/27 23:44:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039421 

最近更新日期:

Date of Last Refreshed on:

2020-10-27 23:31:19 

注册时间:

Date of Registration:

2020-10-27 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

九味竺黄散治疗小儿咳嗽随机对照研究

Public title:

A randomized controlled trial for Jiuwei zhuhuang powder in the treatment of infantile cough

注册题目简写:

English Acronym:

研究课题的正式科学名称:

九味竺黄散治疗小儿咳嗽随机对照研究

Scientific title:

A randomized controlled trial for Jiuwei zhuhuang powder in the treatment of infantile cough

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谢建荣 

研究负责人:

彭韶 

Applicant:

XIE JIANRONG 

Study leader:

PENG SHAO 

申请注册联系人电话:

Applicant telephone:

+86 18911614806

研究负责人电话:

Study leader's telephone:

+86 13838067954

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1710061521@qq.com

研究负责人电子邮件:

Study leader's E-mail:

pengshaodh630@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区望京北路9号叶青大厦D座7层

研究负责人通讯地址:

河南省郑州市建设东路1号

Applicant address:

7 / f, block D, yeqing building, 9 wangjing north road, chaoyang district, Beijing

Study leader's address:

1 jianshe dong lu, zhengzhou city, henan province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

郑州大学第一附属医院

Applicant's institution:

The first affiliated hospital of zhengzhou university

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SS-2019-070

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

郑州大学第一附属医院科研和临床试验伦理委员会

Name of the ethic committee:

Ethics committee of scientific research and clinical trials, the first affiliated hospital of zhengzhou university

伦理委员会批准日期:

Date of approved by ethic committee:

2019-12-02 00:00:00

伦理委员会联系人:

田丽

Contact Name of the ethic committee:

TIAN LI

伦理委员会联系地址:

河南省郑州市建设东路1号

Contact Address of the ethic committee:

1 jianshe dong lu, zhengzhou city, henan province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

郑州大学第一附属医院

Primary sponsor:

The first affiliated hospital of zhengzhou university

研究实施负责(组长)单位地址:

河南省郑州市建设东路1号

Primary sponsor's address:

1 jianshe dong lu, zhengzhou city, henan province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

He'nan

City:

Zhengzhou

单位(医院):

郑州大学第一附属医院

具体地址:

建设东路1号

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Address:

1 Jianshe Road East, Erqi District

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

He'nan

City:

Zhenzhou

单位(医院):

河南中医药大学第一附属医院

具体地址:

人民路19号

Institution
hospital:

The First Affiliated Hospital of henan University of Traditional Chinese Medicine

Address:

19 Renmin Road

国家:

中国

省(直辖市):

河南

市(区县):

开封

Country:

China

Province:

He'nan

City:

Kaifeng

单位(医院):

河南大学淮河医院

具体地址:

鼓楼区包公湖北路8号

Institution
hospital:

Huaihe Hospital of Henan University

Address:

8 Baogonghu Road, Gulou District

经费或物资来源:

自筹

Source(s) of funding:

self-raised

Target disease:

cough

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索九味竺黄散治疗急性上呼吸道感染伴发咳嗽症状患儿的有效性及安全性  

Objectives of Study:

To explore the efficacy and safety of jiuwei zhuhuang powder in treating children with acute upper respiratory tract infection accompanied by cough

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1 经诊断为小儿急性上呼吸道感染患者且以咳嗽为主诉症状(≥2分),发病时间为48h之内
2 藏医“羌蔡”辨证标准
3 年龄:2~14 岁

Inclusion criteria

1 The patient was diagnosed as a child with acute upper respiratory tract infection, and cough was the main symptom (≥2 points), and the onset time was within 48h
2 syndrome differentiation for Tibetan medicine "qiang cai"
3 Age: 2 ~ 14 years old

排除标准:

1 重度营养不良,或伴有其他心血管、肝、肾和造血系统等严重全身性疾病患儿,精神病患儿,对本药过敏患儿。
2 EB (Epstein-Barrvirus,EBV)病毒感染、支原体感染、危险度较高的上呼吸道疾病及呼吸道传染病的患儿。
3 毛细支气管炎、支气管炎、肺炎等下呼吸道感染患儿。
4 发病后已服用抗感冒或止咳药物(含西药、中药等)的患儿

Exclusion criteria:

1 Children with severe malnutrition, or accompanied by other serious systemic diseases such as cardiovascular, liver, kidney and hematopoietic system, children with mental disorders, and children allergic to this medicine.
2 Children with epstein-barrvirus (EBV) infection, mycoplasma infection, high risk of upper respiratory tract diseases and respiratory infectious diseases.
3 Children with bronchiolitis, bronchitis, pneumonia and other lower respiratory tract infections.
4 Children who have taken anti-cold or cough medicine (including western medicine and traditional Chinese medicine) after onset

研究实施时间:

Study execute time:

From 2019-08-01 00:00:00 To 2021-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-12-01 00:00:00 To 2021-04-30 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

63

Group:

experimental group

Sample size:

干预措施:

九味竺黄散

干预措施代码:

Intervention:

jiuwei zhuhuang powder

Intervention code:

组别:

对照组

样本量:

63

Group:

control group

Sample size:

干预措施:

小儿氨酚黄那敏颗粒

干预措施代码:

Intervention:

Acetaminophen flavamine granules for children

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China 

Province:

He'nan 

City:

Zhenzhou 

单位(医院):

郑州大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China 

Province:

He'nan 

City:

Zhenzhou 

单位(医院):

河南中医药大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

开封 

Country:

China 

Province:

He'nan 

City:

Kaifeng 

单位(医院):

河南大学淮河医院 

单位级别:

三级甲等 

Institution
hospital:

Huaihe Hospital of Henan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

咳嗽

指标类型:

主要指标

Outcome:

Cough

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温

指标类型:

次要指标

Outcome:

Body temperature

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鼻塞

指标类型:

次要指标

Outcome:

Nasal congestion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

流涕

指标类型:

次要指标

Outcome:

Runny nose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

喷嚏

指标类型:

次要指标

Outcome:

Sneeze

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 2 years
最大 Max age 14 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由各分中心研究者采用随机数字表法对受试者进行分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers at each sub-center used the random number table method to group the subjects

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NK

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-10-27 23:17:48